uploads/2018/05/ABBV3.png

Analyzing AbbVie’s Product Performance

By

Updated

Creon and Lupron

Sales of AbbVie’s (ABBV) Creon increased from $185 million in 1Q17 to $209 million in 1Q18. This increase was due to an expansion in the drug’s market size and a rise in its market share. Notably, Creon maintains its leadership position in the pancreatic enzyme market.

Total Lupron sales increased from $194 million in 1Q17 to $219 million in 1Q18. Its US sales increased from $155 million in 1Q17 to $177 million in 1Q18. Lupron’s international sales increased by $3 million from $39 million in 1Q17 to $42 million in 1Q18.

Article continues below advertisement

Synthroid

Sales of Synthroid fell 5.3% from $192 million in 1Q17 to $182 million in 1Q18. Synagis sales rose 7% from $300 million in 1Q17 to $321 million in 1Q18. Notably, sales from Androgel fell 4.6% from $136 million in 1Q17 to $130 million in 1Q18.

On the other hand, as a result of increased market penetration, total Duodopa sales grew 28.9% from $80 million in 1Q17 to $103 million in 1Q18. The drug’s US sales grew ~31% from $14 million in 1Q17 to $18 million in 1Q18. Its international sales grew 28.5% from $66 million in 1Q17 to $85 million in 1Q18.

Sevoflurane and Kaletra

Sevoflurane sales fell marginally from $107 million in 1Q17 to $106 million in 1Q18. Kaletra sales, on the other hand, registered a 36% fall in total sales from $115 million in 1Q17 to $73 million in 1Q18. The drug’s US sales decreased from $19 million in 1Q17 to $13 million in 1Q18. Its international sales decreased from $96 million in 1Q17 to $60 million in 1Q18.

In the next part of the series, we’ll take a look at AbbVie’s research pipeline.

Advertisement

More From Market Realist